Vertex Pharmaceuticals (VRTX) reported 2.65billioninrevenueforthequarterendedJune2024,representingayear−over−yearincreaseof6.112.83 for the same period compares to 3.89ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof2.65 billion, representing a surprise of -0.08%. The company delivered an EPS surprise of -11.57%, with the consensus EPS estimate being -$11.50. While investors scrutinize revenue and earnings changes year-over-year and how they compar ...